

Neuroleptic malignant syndrome in covid-19 pediatrics

Dicle Sener Okur

State Hospital of Denizli, Turkey

Abstract

Neuroleptic malignant syndrome (NMS) is a clinical condition associated with the use of antipsychotics and drugs that affect the dopaminergic system, characterized by extrapyramidal symptoms, autonomic dysfunction. NMS during COVID-19 infection has not been previously described among children. In this report, we reported a paediatric patient who was followed up because of NMS developed during the COVID-19 infection course. Neuroleptic malignant syndrome (NMS) is a clinical condition associated with the use of antipsychotics and drugs that affect the dopaminergic system, characterized by extrapyramidal symptoms, autonomic dysfunction. NMS during COVID-19 infection has not been previously described among children. In this report, we reported a paediatric patient who was followed up because of NMS developed during the COVID-19 infection course.

Received: March 10, 2022; **Accepted:** March 17, 2022; **Published:** March 24, 2022.

Biography

Dicle Sener Okur was born at 1980 in Ankara, Turkey. She has graduated from Ege University Faculty of Medicine at 2004, between 2004-2010 worked in Istanbul University, Istanbul Faculty of Medicine, Department of Pediatrics.

In 2014, she has graduated from Istanbul University, Cerrahpasa Faculty of Medicine, Department of Pediatrics as Pediatric Infectious Diseases specialist.